Munire Adilijiang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Munire Adilijiang has a total of 4 co-authors. Here are the top co-authors by number of shared publications:
- Caihua Chang
Department of Infectious Diseases People's Hospital of Xinjiang Uygur Autonomous Region Urumqi China
1 shared publication - Hai-Yin Jiang
Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China
1 shared publication - Jiangshan Lian
State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, School of Medicine, Zhejiang University, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, Hangzhou 310003, China
1 shared publication - Yongping Zhang
Department of Hematology Aerospace Center Hospital Beijing China
1 shared publication
Latest Publications
- 10 August 2021
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 88 (3) , 911-918
Neonatal outcomes after neuraminidase inhibitor use during pregnancy: A meta‐analysis of cohort studies
Aim: Influenza infection poses a severe threat to pregnant mothers, and antiviral treatment is recommended. However, the safety of neuraminidase‐inhibitor antiviral medications during pregnancy has not been well described.Methods: A systematic review and meta‐analysis were performed to evaluate the adverse neonatal outcomes associated with exposure to neuraminidase inhibitors during pregnancy. The PubMed, Embase and Cochrane Library databases were searched to identify potential studies for inclusion.Results: Nine cohort studies that estimated adverse neonatal outcomes associated with exposure to neuraminidase‐inhibitor medication during pregnancy were included. Exposure to a neuraminidase inhibitor during pregnancy was not associated with an increased risk of congenital malformation (odds ratio [OR] 0.9, 95% confidence interval [CI] 0.72‐1.12, P = .341), low Apgar score (OR 0.96, 95% CI 0.77‐1.2, P = .733) or preterm birth (OR 0.99, 95% CI 0.89‐1.09, P = .771) compared with no exposure. However, exposure to a neuraminidase inhibitor was associated with a reduced risk of low birth weight (OR 0.79, 95% CI 0.68‐0.92, P = .002) and giving birth to a small‐for‐gestational‐age infant (OR 0.78, 95% CI 0.69‐0.88, P < .001). Further analyses limited to oseltamivir exposure were consistent with the overall results.Conclusion: Exposure to neuraminidase‐inhibitor medication during pregnancy does not appear to be associated with adverse neonatal outcomes. We recommend further studies to investigate this association, which will help clinicians determine whether to prescribe a neuraminidase inhibitor during pregnancy.
- 10 August 2021
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 88 (3) , 911-918
Neonatal outcomes after neuraminidase inhibitor use during pregnancy: A meta‐analysis of cohort studies
Aim: Influenza infection poses a severe threat to pregnant mothers, and antiviral treatment is recommended. However, the safety of neuraminidase‐inhibitor antiviral medications during pregnancy has not been well described.Methods: A systematic review and meta‐analysis were performed to evaluate the adverse neonatal outcomes associated with exposure to neuraminidase inhibitors during pregnancy. The PubMed, Embase and Cochrane Library databases were searched to identify potential studies for inclusion.Results: Nine cohort studies that estimated adverse neonatal outcomes associated with exposure to neuraminidase‐inhibitor medication during pregnancy were included. Exposure to a neuraminidase inhibitor during pregnancy was not associated with an increased risk of congenital malformation (odds ratio [OR] 0.9, 95% confidence interval [CI] 0.72‐1.12, P = .341), low Apgar score (OR 0.96, 95% CI 0.77‐1.2, P = .733) or preterm birth (OR 0.99, 95% CI 0.89‐1.09, P = .771) compared with no exposure. However, exposure to a neuraminidase inhibitor was associated with a reduced risk of low birth weight (OR 0.79, 95% CI 0.68‐0.92, P = .002) and giving birth to a small‐for‐gestational‐age infant (OR 0.78, 95% CI 0.69‐0.88, P < .001). Further analyses limited to oseltamivir exposure were consistent with the overall results.Conclusion: Exposure to neuraminidase‐inhibitor medication during pregnancy does not appear to be associated with adverse neonatal outcomes. We recommend further studies to investigate this association, which will help clinicians determine whether to prescribe a neuraminidase inhibitor during pregnancy.